arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Estrella Immunopharma, Inc.

ESLA

$0.77 ▲ +0.03 (+3.43%) at close

15 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Estrella Immunopharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $32.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 34.4% ↗

FCF / Share $-0.16

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

15-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-2.29M

↓ -8.9% —

FCF / Share Free cash flow per share

$-0.16

↓ -1134.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Jun 30, 2023 10-K ↗	Q3 FY2024 Sep 30, 2022 10-Q ↗	Q2 FY2024 Jun 30, 2022 10-Q ↗	Q1 FY2024 Mar 31, 2022 10-Q ↗	Q4 FY2023 Dec 31, 2021 10-K ↗	Q3 FY2023 Sep 30, 2021 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2021 10-Q ↗	Q4 FY2022 Jan 31, 2021 10-K ↗	Q1 FY2022 Jan 31, 2021 10-Q ↗
EPS Growth YoY (%)	16.7% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	100.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-62.5% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-150.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-200.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	—	91.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-100.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	99.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-8.9% Weak ↑ Weak Improving Year-over-year change in net income	81.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-1389.8% Weak → Weak Stable Year-over-year change in net income	-1389.8% Weak ↑ Weak Improving Year-over-year change in net income	-1389.8% Weak ↑ Weak Improving Year-over-year change in net income	N/M	-17146.9% Weak ↓ Weak Declining Year-over-year change in net income	92.4% Excellent Excellent Year-over-year change in net income	-17146.9% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	-1134.9% Weak Weak Year-over-year change in free cash flow	—	—	—	88.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-13415.0% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Jun 30, 2023 10-K ↗	Q3 FY2024 Sep 30, 2022 10-Q ↗	Q2 FY2024 Jun 30, 2022 10-Q ↗	Q1 FY2024 Mar 31, 2022 10-Q ↗	Q4 FY2023 Dec 31, 2021 10-K ↗	Q3 FY2023 Sep 30, 2021 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2021 10-Q ↗	Q4 FY2022 Jan 31, 2021 10-K ↗	Q1 FY2022 Jan 31, 2021 10-Q ↗
Effective Tax Rate (%) (%)	—	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	2.92x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.29x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.35x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.20x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.22x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	-1.63x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.11x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	0.12x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	—	6.02x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	1.00x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Jun 30, 2023 10-K ↗	Q3 FY2024 Sep 30, 2022 10-Q ↗	Q2 FY2024 Jun 30, 2022 10-Q ↗	Q1 FY2024 Mar 31, 2022 10-Q ↗	Q4 FY2023 Dec 31, 2021 10-K ↗	Q3 FY2023 Sep 30, 2021 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2021 10-Q ↗	Q4 FY2022 Jan 31, 2021 10-K ↗	Q1 FY2022 Jan 31, 2021 10-Q ↗
Return on Invested Capital (%)	34.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	-14.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	22.3% Excellent → Excellent Stable Return earned on debt + equity capital invested Optimal: > 10%	27.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	28.1% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	12.6% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	-808.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	—	6.9% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	-3.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-62.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-19.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	-109.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-1.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-0.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-0.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	17.8% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	—	-33.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-0.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	43.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+190%)	-14.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-196%)	—	—	—	28.2% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+88%)	7.1% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-52%)	9.4% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-38%)	12.3% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-18%)	—	—	15.9% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+6%)	-3.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-123%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Jun 30, 2023 10-K ↗	Q3 FY2024 Sep 30, 2022 10-Q ↗	Q2 FY2024 Jun 30, 2022 10-Q ↗	Q1 FY2024 Mar 31, 2022 10-Q ↗	Q4 FY2023 Dec 31, 2021 10-K ↗	Q3 FY2023 Sep 30, 2021 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2021 10-Q ↗	Q4 FY2022 Jan 31, 2021 10-K ↗	Q1 FY2022 Jan 31, 2021 10-Q ↗
Net Debt (USD)	—	$-1.38M	—	—	—	$-2.48M	$-73.75K	$-88.28K	$-321.72K	$-478.87K	—	$-2.48M	$-321.72K	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Jun 30, 2023 10-K ↗	Q3 FY2024 Sep 30, 2022 10-Q ↗	Q2 FY2024 Jun 30, 2022 10-Q ↗	Q1 FY2024 Mar 31, 2022 10-Q ↗	Q4 FY2023 Dec 31, 2021 10-K ↗	Q3 FY2023 Sep 30, 2021 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2021 10-Q ↗	Q4 FY2022 Jan 31, 2021 10-K ↗	Q1 FY2022 Jan 31, 2021 10-Q ↗
Basic EPS, GAAP (USD)	$-0.05	$-0.01	$-0.13	$-0.15	$-0.06	$-36.13	$-0.08	$-0.06	$-0.02	—	$-0.99	$-0.03	$-2.06	—	—
Free Cash Flow per Share (USD)	$-0.16	—	$-0.02	$-0.01	$-0.01	—	—	—	$-0.11	—	—	$-0.32	$-0.00	—	—
Book Value per Share (USD)	$-0.13	—	—	—	—	$-12.00	$-1.40	$-1.06	$-0.81	$-0.71	—	$-12.00	$0.02	$0.00	$0.00
Tangible Book Value per Share (USD)	$-0.13	—	—	—	—	$-12.00	$-1.40	$-1.06	$-0.81	$-0.71	—	$-12.00	$0.02	$0.00	$0.00
Basic Weighted Avg Shares (shares)	42.12M	—	37.10M	36.17M	36.19M	—	1.42M	1.42M	1.42M	—	1.28M	35.20M	1.00M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Jun 30, 2023 10-K ↗	Q3 FY2024 Sep 30, 2022 10-Q ↗	Q2 FY2024 Jun 30, 2022 10-Q ↗	Q1 FY2024 Mar 31, 2022 10-Q ↗	Q4 FY2023 Dec 31, 2021 10-K ↗	Q3 FY2023 Sep 30, 2021 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2021 10-Q ↗	Q4 FY2022 Jan 31, 2021 10-K ↗	Q1 FY2022 Jan 31, 2021 10-Q ↗
Working Capital (USD)	$-6.77M	$-11.87M	—	—	—	$-7.01M	$-575.00K	$-25.82K	$397.94K	$542.88K	—	$-7.01M	$542.88K	—	—
Total Equity (USD)	$-5.27M	$4.27M	—	—	—	$-11.74M	$-1.98M	$-1.51M	$-1.15M	$-1.01M	—	$-11.74M	$24.18K	$0.00	$0.00

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Jun 30, 2023 10-K ↗	Q3 FY2024 Sep 30, 2022 10-Q ↗	Q2 FY2024 Jun 30, 2022 10-Q ↗	Q1 FY2024 Mar 31, 2022 10-Q ↗	Q4 FY2023 Dec 31, 2021 10-K ↗	Q3 FY2023 Sep 30, 2021 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2021 10-Q ↗	Q4 FY2022 Jan 31, 2021 10-K ↗	Q1 FY2022 Jan 31, 2021 10-Q ↗
Net Income, GAAP (USD)	$-2.29M	$-613.17K	$-2.10M	$-2.10M	$-2.10M	$-3.32M	$-141.25K	$-141.25K	$-141.25K	$8.14M	$-819.00	$-1.87M	$-819.00	—	—
Operating Cash Flow (USD)	$-6.70M	$-177.49K	$-727.33K	$-414.88K	$-465.98K	$5.41M	—	—	$-157.14K	$976.72K	—	$-11.27M	$-819.00	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 15 quarters

Estrella Immunopharma, Inc.

Analytical Summary

15-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ESLA with peers